[go: up one dir, main page]

BR0114082A - Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas - Google Patents

Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas

Info

Publication number
BR0114082A
BR0114082A BR0114082-5A BR0114082A BR0114082A BR 0114082 A BR0114082 A BR 0114082A BR 0114082 A BR0114082 A BR 0114082A BR 0114082 A BR0114082 A BR 0114082A
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
manufacture
preparation
relates
Prior art date
Application number
BR0114082-5A
Other languages
English (en)
Inventor
Thomas Weller
Martin Bolli
Christoph Boss
Martine Clozel
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR0114082A publication Critical patent/BR0114082A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS, COMPOSIçõES FARMACêUTICAS, USO DE UM OU MAIS COMPOSTOS, E, PROCESSO PARA A FABRICAçãO DE COMPOSIçõES FARMACêUTICAS". A invenção diz respeito a novas arilalcano-sulfonamidas e a seu uso como ingredientes ativos na preparação de composições farmacêuticas. A invenção também diz respeito a aspectos relacionados, incluindo processos para a preparação dos compostos, das composições farmacêuticas que contenham um ou mais daqueles compostos e, especialmente, a seu uso como antagonistas do receptor da endotelina.
BR0114082-5A 2000-09-25 2001-08-28 Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas BR0114082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0009327 2000-09-25
PCT/EP2001/009894 WO2002024665A1 (en) 2000-09-25 2001-08-28 Arylalkane-sulfonamides having endothelin-antagonist activity

Publications (1)

Publication Number Publication Date
BR0114082A true BR0114082A (pt) 2003-07-22

Family

ID=8164105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114082-5A BR0114082A (pt) 2000-09-25 2001-08-28 Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas

Country Status (18)

Country Link
US (1) US7091201B2 (pt)
JP (1) JP2004509874A (pt)
KR (1) KR100835770B1 (pt)
CN (1) CN1326841C (pt)
AR (1) AR032896A1 (pt)
AT (1) ATE446289T1 (pt)
AU (2) AU1217102A (pt)
BR (1) BR0114082A (pt)
CA (1) CA2423351C (pt)
DE (1) DE60140263D1 (pt)
ES (1) ES2333409T3 (pt)
HU (1) HUP0303364A3 (pt)
IL (1) IL154364A0 (pt)
MX (1) MXPA03001991A (pt)
NO (1) NO20031332L (pt)
NZ (1) NZ524172A (pt)
WO (1) WO2002024665A1 (pt)
ZA (1) ZA200302292B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
ES2548022T3 (es) 2004-03-05 2015-10-13 F. Hoffmann-La Roche Ag Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
RS53145B (sr) 2004-08-28 2014-06-30 Astrazeneca Ab. Pirimidin sulfonamidni derivati kao modulatori hemokinskih receptora
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
BRPI0615613A2 (pt) 2005-09-01 2009-05-19 Hoffmann La Roche diaminopirimidinas como moduladores de p2x3 e p3x2/3
US9181231B2 (en) * 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
CN103864701B (zh) * 2014-03-10 2016-08-24 常熟市金申医化制品有限责任公司 4-磺胺-5-甲氧基-6-氯嘧啶的制备方法
WO2020083975A1 (en) 2018-10-23 2020-04-30 Step Pharma S.A.S. Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
WO2020245665A1 (en) * 2019-06-04 2020-12-10 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
DK3980411T3 (da) * 2019-06-04 2025-10-13 Step Pharma S A S N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1549494A (pt) 1967-10-31 1968-12-13
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
JP2790065B2 (ja) * 1993-12-17 1998-08-27 田辺製薬株式会社 ベンゼンスルホンアミド誘導体及びその製法
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
JP3013752B2 (ja) * 1995-05-16 2000-02-28 田辺製薬株式会社 スルホンアミド誘導体
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
JP3067131B2 (ja) * 1995-06-16 2000-07-17 田辺製薬株式会社 医薬組成物
CN1102580C (zh) 1995-12-20 2003-03-05 山之内制药株式会社 芳基乙烯基磺酰胺衍生物及其医药组合物
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物
AU8035698A (en) * 1997-06-19 1999-01-04 Yamanouchi Pharmaceutical Co., Ltd. Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same
JPH11343239A (ja) * 1998-03-31 1999-12-14 Tanabe Seiyaku Co Ltd 排尿障害の予防・治療剤

Also Published As

Publication number Publication date
WO2002024665A1 (en) 2002-03-28
HUP0303364A3 (en) 2004-04-28
CN1633418A (zh) 2005-06-29
KR20030029979A (ko) 2003-04-16
NZ524172A (en) 2004-09-24
AU2002212171B2 (en) 2006-12-14
HUP0303364A2 (hu) 2004-03-01
AU1217102A (en) 2002-04-02
KR100835770B1 (ko) 2008-06-09
NO20031332D0 (no) 2003-03-24
NO20031332L (no) 2003-03-24
US20040102464A1 (en) 2004-05-27
US7091201B2 (en) 2006-08-15
CA2423351A1 (en) 2002-03-28
MXPA03001991A (es) 2003-06-24
CN1326841C (zh) 2007-07-18
JP2004509874A (ja) 2004-04-02
WO2002024665A8 (en) 2002-06-06
ES2333409T3 (es) 2010-02-22
ATE446289T1 (de) 2009-11-15
CA2423351C (en) 2010-12-21
DE60140263D1 (de) 2009-12-03
IL154364A0 (en) 2003-09-17
ZA200302292B (en) 2004-06-30
AR032896A1 (es) 2003-12-03

Similar Documents

Publication Publication Date Title
BRPI0109200B8 (pt) compostos e composições farmacêuticas
BR0116237A (pt) Compostos, composições farmacêuticas, uso de qualquer um ou mais compostos, e, processo para a manufatura de composições farmacêuticas
BR0114082A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BRPI0206636B8 (pt) composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BR0116505A (pt) Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
BR0211729A (pt) Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BR0312000A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
EP1291362A4 (en) COMPLEX OF FOLIC ACID AND POLYSACCHARIDES, THE PRODUCTION THEREOF AND THE COMPLEX COMPRISING THE COMPOSITION COMPRISING THE ACTIVE INGREDIENT COMPOSITION
BR0112614A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos e processo para a fabricação de composições farmacêuticas
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements